Detalles de la búsqueda
1.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493792
2.
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Cancer Sci
; 112(6): 2381-2392, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33686753
3.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Oncologist
; 26(1): e53-e65, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32955138
4.
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Breast Cancer Res Treat
; 186(2): 417-428, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33392835
5.
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Oncologist
; 25(9): e1346-e1354, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32536013
6.
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Oncologist
; 25(2): e243-e251, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32043763
7.
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Breast Cancer Res Treat
; 184(1): 161-172, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32789591
8.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.
Lancet Oncol
; 24(3): e104, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36858725
9.
A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors.
Invest New Drugs
; 36(4): 647-656, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29453627
10.
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
Invest New Drugs
; 35(4): 442-450, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28161886
11.
12.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Oncologist
; 26(3): e522, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33660385
13.
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
NPJ Breast Cancer
; 10(1): 34, 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38671001
14.
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
J Clin Oncol
; 42(9): 987-993, 2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194616
15.
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Invest New Drugs
; 31(4): 1023-34, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23397500
16.
Designing exploratory cancer trials using change in tumour size as primary endpoint.
Stat Med
; 32(15): 2544-54, 2013 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23280944
17.
Regulation of stem cell fate by HSPGs: implication in hair follicle cycling.
NPJ Regen Med
; 7(1): 77, 2022 Dec 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36577752
18.
Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.
Br J Clin Pharmacol
; 71(3): 416-28, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21284701
19.
Microfluidic arrays of dermal spheroids: a screening platform for active ingredients of skincare products.
Lab Chip
; 21(20): 3952-3962, 2021 10 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34636823
20.
Challenging Cosmetic Innovation: The Skin Microbiota and Probiotics Protect the Skin from UV-Induced Damage.
Microorganisms
; 9(5)2021 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33925587